What is the US prevalence of Smith-Lemli-Opitz syndrome (SLOS)?

Updated: Jan 27, 2021
  • Author: Robert D Steiner, MD; Chief Editor: Luis O Rohena, MD, MS, FAAP, FACMG  more...
  • Print
Answer

United States

Prevalence of Smith-Lemli-Opitz syndrome has been estimated to be 1 in 20,000-60,000 births among Caucasians. Smith-Lemli-Opitz syndrome is also not uncommon in Hispanics. Its specific prevalence in different populations has not been precisely determined. The higher-than-expected prevalence of Smith-Lemli-Opitz syndrome suggests a heterozygote advantage.

Only one description of an African-American patient has been published, although no biochemical or molecular confirmation of Smith-Lemli-Opitz syndrome was available. [9] In a study of 150 biochemically diagnosed patients with Smith-Lemli-Opitz syndrome, only one individual was of African descent. [10] In 2000, Yu and colleagues did not detect the mutation among 121 Africans from Sierra Leone. [11] In 2001, Nowaczyk and colleagues reported an IVS8-1G>C (common Smith-Lemli-Opitz syndrome mutation) carrier frequency of 1.09% (17 per 1559 population) in Canadian whites and 0.79% (4 per 504 population) in Canadians of African descent; however, no African Canadian patients were identified. [12]

The results of Wright et al's 2003 study indicate an IVS8-1G>C carrier frequency of 0.73% (10 per 1378 population) in African Americans. [13] This predicts the prevalence of Smith-Lemli-Opitz syndrome due to IVS8-1G>C homozygosity to be 1 case per 75,061 persons in the African American population. Although the African American carrier frequency of the IVS8-1G>C allele was determined to be 0.73%, few African American patients with Smith-Lemli-Opitz syndrome have been identified.

Carrier frequency for Smith-Lemli-Opitz syndrome is approximately 1 in 30 persons of northern European descent, suggesting a disease frequency of 1 per 5000-18,000 people. The actual disease prevalence may be lower because of fetal losses and missed diagnoses or misdiagnoses at the most severe and most mild ends of the severity spectrum.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!